Equibles does not estimate personal net worth.
Get an email with a short summary when Inovio Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.
Get INO alertsJacqueline Shea is recorded as CEO, COO and Board Member at Inovio Pharmaceuticals, Inc. (INO). The proxy statement of Inovio Pharmaceuticals, Inc. reports total compensation of $1,587,155 for Jacqueline Shea in fiscal 2025, including a base salary of $728,000. Disclosed compensation is on record for 7 fiscal years. Jacqueline Shea has spoken on 10 earnings calls and 3 other investor events across 1 company, most recently for Inovio Pharmaceuticals, Inc. on September 11, 2026. Inovio Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Inovio Pharmaceuticals, Inc. includes Jacqueline E. Shea (CEO, COO and Board Member), Simon X. Benito (Chairman and Board Member), Peter D. Kies (CFO) and 6 others.
“It's a pleasure to be here today and tell you about some of the exciting work that we're doing here at Anovio.”
“It's a pleasure to be here today and tell you about some of the exciting work that we're doing here at Anovio.”
“Since our last quarterly call in May, the FDA's review of our BLA for INO 3107 has continued to advance, with several important steps in the regulatory process now complete.”
“I would like to take a few moments today to review the progress Inovio has achieved since our last shareholders meeting. Before I move on to the details I'd like to remind you that I will be making forward-looking statements regarding future events and the future performance of the company.”
“Today, I'm very pleased to share some important updates on the key progress we've made recently. First and foremost, we have achieved our primary objective for this year, which is completing the rolling submission of our BLA for INO-3107.”
Biotechnology · Healthcare
CEO, COO, Board Member
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Inovio Pharmaceuticals, Inc. (INO) | President and Chief Executive Officer | $728,000 | $1,587,155 |
| 2024 | Inovio Pharmaceuticals, Inc. (INO) | President and Chief Executive Officer | $728,000 | $2,050,669 |
| 2023 | Inovio Pharmaceuticals, Inc. (INO) | President and Chief Executive Officer | $750,615 | $2,438,908 |
| 2022 | Inovio Pharmaceuticals, Inc. (INO) | President and Chief Executive Officer | $729,758 | $3,519,118 |
| 2021 | Inovio Pharmaceuticals, Inc. (INO) | President and Chief Executive Officer | $467,585 | $2,310,157 |
| 2020 | Inovio Pharmaceuticals, Inc. (INO) | Chief Operating Officer | $430,769 | $2,137,311 |
| 2019 | Inovio Pharmaceuticals, Inc. (INO) | Chief Operating Officer | $335,000 | $1,157,034 |
